| Literature DB >> 25768348 |
Hee Jeong Yoo1,2, Kyung Kim3,4,5, In Hyang Kim6, Seong-Hwan Rho7, Jong-Eun Park8, Ki Young Lee4,5, Soon Ae Kim9, Byung Yoon Choi2,10, Namshin Kim11.
Abstract
Rubinstein-Taybi syndrome (RSTS) is a rare condition with a prevalence of 1 in 125,000-720,000 births and characterized by clinical features that include facial, dental, and limb dysmorphology and growth retardation. Most cases of RSTS occur sporadically and are caused by de novo mutations. Cytogenetic or molecular abnormalities are detected in only 55% of RSTS cases. Previous genetic studies have yielded inconsistent results due to the variety of methods used for genetic analysis. The purpose of this study was to use whole exome sequencing (WES) to evaluate the genetic causes of RSTS in a young girl presenting with an Autism phenotype. We used the Autism diagnostic observation schedule (ADOS) and Autism diagnostic interview revised (ADI-R) to confirm her diagnosis of Autism. In addition, various questionnaires were used to evaluate other psychiatric features. We used WES to analyze the DNA sequences of the patient and her parents and to search for de novo variants. The patient showed all the typical features of Autism, WES revealed a de novo frameshift mutation in CREBBP and de novo sequence variants in TNC and IGFALS genes. Mutations in the CREBBP gene have been extensively reported in RSTS patients, while potential missense mutations in TNC and IGFALS genes have not previously been associated with RSTS. The TNC and IGFALS genes are involved in central nervous system development and growth. It is possible for patients with RSTS to have additional de novo variants that could account for previously unexplained phenotypes.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25768348 PMCID: PMC4394500 DOI: 10.3390/ijms16035697
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Physical characteristics of the proband. Patient’s eyes are covered for reasons of confidentiality. Typical facial dysmorphic features can be observed in (A,B), including highly arched eyebrows, a broad nasal bridge, beaked nose with the nasal septum extending well below the alae, a pouting lower lip, and mild micrognathia. Dental crowding is shown in (C); The hand and feet abnormalities are shown in (D,E), showing short and broad big toes and thumbs, as well as mild clinodactyly on the 5th digit of both hands. The 2nd, 3rd, 4th digits of the right hand had short distal phalanges and the 3rd, 4th digits of the left hand had broad distal phalanges. The X-ray of the left hand shows delayed carpal bone ossification and prominent thickening of the soft tissue of all fingers (F); The X-ray of the feet shows bilateral pes varus deformities and abnormalities in the physes of big toe metatarsal bones (G); Growth curve (H) shows marked growth retardation in the proband (blue dot) superimposed on the normal growth curve of Korean girls of age 2 to 18 (black line). The growth curve shows the height and weight changes of the patient over time. These values never exceeded the third percentile since birth. Data for normal growth curve came from the Korea Center for Disease Control and Prevention.
Figure 2Schematic of de novo variants of CREBBP, IGFALS, and TNC in RSTS. (A) Genomic alterations and schematic drawing of proteins showing the predicted effects of selected missense mutations identified in CREBBP. The p.Thy1174Cys and p.Thr910Ala substitutions predicted by missense mutations do not affect known functional domains and are associated with a mild phenotype compared with the classic phenotype expected for mutations at other sites. The frameshift mutation p.Gln733Hisfs*5 is predicted to interrupt all of the following functional domains: BAD, CH2, HAT, CH3, and CTAD; (B) The IGFALS mutation site affects the LRR domain and (C) the TNC mutation one of the EGF-like repeats. The de novo variants are shown in red. CREBBP: CREB (cAMP response element-binding protein) binding protein; IGFALS: Insulin-like growth factor)-binding protein, acid labile subunit; TNC: Tenascin C; Protein domain names: (A) NHRD: Nuclear receptor-binding and receptor-interacting domain; NTAD: Amino-terminal transactivation domain; CH1: Cys/His-rich region; CREB/KIX: CREB-binding domain; BROMO/BRD: Bromo domain; HAT: Histone acetyltransferase domain; CH2: Cys/His-rich region 2; CH3: Cys/His-rich region 3; CTAD: C-terminal transactivation domain; (B) NH2: N-terminal; CH1: Cys-rich region 1; LRR: Leucine rich repeats; CH2: Cys-rich region 2; COOH: C-terminal; (C) TA: N-terminal tenascin assembly domain; EGF-like repeats: Epidermal growth factor-like repeats; FNIII repeats: Fibronectin type III-like repeats; FN Globe: C-terminal fibrinogen globe
The three de novo variants validated by Sanger Sequencing.
| Gene | |||
|---|---|---|---|
| chr9 | chr16 | chr16 | |
| 117852975 | 1841118 | 3823901 | |
| C | G | C | |
| T | A | – | |
| Missense | Missense | Frameshift | |
| c.323G>A | c.1415C>T | c.2199delG | |
| p.Arg108His | p.Ala472Val | p.Gln733Hisfs*5 | |
| 2.369 | 0.598 | 1.492 | |
| 1200.8 | 2536.4 | 476.2 | |
| 0 | 0.30 | – | |
| 1.87 | 0.995 | – | |
| Likely pathogenic 2 | Variants of unknown significance | Pathogenic |
1 Variant Classification is based on the recommendations of Ambry Genetics, but pathogenicity of de novo variants in TNC and IGFALS are not certain; 2 TNC c.323G>A is reported in dbSNP as rs151119387, but MAF/MinorAlleleCount = 0.0002/1. Overall MAF in 1000 genomes, ESP6500, ExAc database is less than 0.0003. TNC: Tenascin C; IGFALS: Insulin-like growth factor-binding protein, acid labile subunit; CREBBP: CREB (cAMP response element-binding protein) binding protein; phyloP: Phylogenetic p-values; GERP: Genomic evolutionary rate profiling; SIFT: Sorting intolerant from tolerant.
Figure 3Sequences of CREBBP, IGFALS, and TNC for the family trio. A downward arrow indicates the mutated residue and nucleotides are shown in colored, single-letter codes. The black circle indicates the proband.
Figure 4Validation results for de novo variants in CREBBP, IGFALS, and TNC in 80 normal Korean subjects. The downward arrow indicates the residue of de novo variants.